Clinical trials in Lille – page 10

1 340 clinical trials in Lille, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Lille at a glance

1 340

clinical trials

Research sites3

Quick filters

1 340 trials in Lille

Open in trial search

Peripheral arterial occlusive disease+5

Recruiting

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Clopidogrel
Sponsor:Fondation Hopital Saint Joseph

Contact Research Centre

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

France

Participants:18–64 years · 65+ years
Substances:SAR445399
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Interstitial lung disease+1

Recruiting

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational

France

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:BI 1015550
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Acute myocardial infarction

Recruiting

A study of tirofiban and adenosine to treat small blood vessel damage in patients with ST-elevation myocardial infarction

Registered drugNo placebo

A study of tirofiban and adenosine to treat small blood vessel damage in patients with ST-elevation myocardial infarction

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Adenosine

Contact Research Centre

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational

France

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Contact Research Centre

Cerebral haemorrhage

Recruiting

A study to evaluate the use of diroximel fumarate to reduce brain swelling in patients with a stroke caused by bleeding in the brain.

Registered drug

A study to evaluate the use of diroximel fumarate to reduce brain swelling in patients with a stroke caused by bleeding in the brain.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Diroximel Fumarate
Sponsor:Centre Hospitalier Universitaire De Lille

Contact Research Centre

Neoplasm malignant

Recruiting

A study of DS-3790A, rituximab, and epcoritamab in patients with blood cancers

Registered drugNo placebo

A study of DS-3790A, rituximab, and epcoritamab in patients with blood cancers

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Acute leukaemia

Recruiting

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Sumitomo Pharma America Inc.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

France

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Squamous cell carcinoma of the hypopharynx+1

Recruiting

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Centre Leon Berard

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Lille

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma, exploring novel treatment combinations and targeted therapies. Additional research includes investigations into pancreatic cancer and gastric cancer treatments.

Advanced cancer therapies
Targeted molecular treatments
Combination therapy approaches

Studies are evaluating innovative therapeutic agents and their effectiveness in treating various forms of cancer.

02 Neurological Disorders

Comprehensive research into Alzheimer's disease and Amyotrophic Lateral Sclerosis, examining new treatment approaches and disease mechanisms. Studies also include investigations of essential tremor treatments.

Neurodegenerative diseases
Movement disorders
Brain imaging studies

Research focuses on understanding disease progression and developing targeted interventions.

03 Autoimmune and Inflammatory Conditions

Innovative trials examining treatments for Crohn's disease and Multiple Sclerosis. Research includes novel approaches to managing chronic inflammatory conditions and immune system disorders.

Inflammatory bowel diseases
Immunotherapy approaches
Disease modification strategies

Studies aim to improve treatment outcomes and develop more effective therapeutic options.

Back to France All countries